Table 1.
Drugs evaluated in clinical trials for the treatment of COVID-19 (not exhaustive).
| Drug | Company | Current use and/or initial target | Mode of Action | Mode of Administration | Clinical trials for COVID-19 (examples) (NCI)(not exhaustive) |
|---|---|---|---|---|---|
| Antiviral | |||||
| Remdesivir | Gilead | Experimental, Ebola | Nucleotide analogue | intravenous | NCT04252664; NCT04280705; Solidarity (WHO); NCT04292899 |
| Chloroquine/hydroxychloroquine (Aralen/Plaquenil) | Sanofi | Malaria | Heme polymerase inhibitor | Oral | NCT04333732; NCT04341727; NCT04358068; NCT04315948 |
| Lopinavir + ritonavir (Kaletra) | AbbVie | HIV | Protease inhibitor | Oral | NCT04307693; NCT04372628; NCT04255017; NCT04276688 |
| Favipiravir (Avigan) | Fujifilm | Experimental, Influenza | RNA polymerase inhibitor | Oral | NCT04333589; NCT04310228; NCT04346628 |
| Umifenovir (Arbidol) | Pharmstandard | Experimental, Influenza | Inhibits membrane fusion (entry) | Oral | NCT04333589 |
| Camostat | Ono Pharmaceutical | Experimental | Protease inhibitor | Oral | NCT04374019 |
| Ribavirin | Bausch Health | Hepatitis C | Lower respiratory tract infection due to RSV | Inhalation | NCT04356677 |
| Anti-inflammatory | |||||
| Interferon alfa-2b | Hepatitis C | Immune modulator | Sub-cutaneous | NCT04349410 | |
| Tocilizumab (Actemra) | Roche | Rheumatoid arthritis | IL-6R Ab | intravenous | NCT04310228; NCT04331795; NCT04320615; NCT04310228 |
| Sarilumab (Kevzara) | Sanofi | Rheumatoid arthritis | IL-6R Ab | intravenous | NCT04315298; NCT04359901 |
| Baricitinib (Olumiant) | Eli Lilly | Rheumatoid arthritis | Inhibition of JAK | Oral | NCT04340232; NCT04373044 |
Ab, antibody; COVID-19, coronavirus disease 2019; RSV, respiratory syncytial virus.